Efficacy and safety of ketotifen eye drops as adjunctive therapy to mometasone nasal spray in subjects with seasonal allergic rhinoconjunctivitis

Clinical Drug Investigation

Volumn 23, Issue 9, 2003, Pages 597-604

  Horak, F ^a   Stuebner, P ^a   Zieglmayer, R ^a   McWhirter, C L ^b   Gekkieva, M ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Novartis Ophthalmics Inc   (United States)

^c Novartis Ophthalmics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; EYE DROPS; KETOTIFEN FUMARATE; MOMETASONE FUROATE; PLACEBO;

ADULT; ALLERGY; AREA UNDER THE CURVE; ARTICLE; BIOMICROSCOPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; EYE REDNESS; FEMALE; HAY FEVER; HUMAN; MALE; NOSE DISEASE; OCULAR PRURITUS; PHARYNGITIS; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SEASONAL VARIATION; SNEEZING; TREATMENT OUTCOME;

EID: 0141613189     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323090-00006     Document Type: Article

References (25)

1. Burkholter D, Schiffer P. The epidemiology of atopic diseases in Europe: a review. Allergy Clin Immunol News 1995; 7: 113-25
2. Bachert C, Vovolis V, Margari P, et al. Mizolastine in the treatment of seasonal allergic rhinoconjunctivitis: a European clinical experience with 5408 patients managed in daily practice (PANEOS SAR Study). Allergy 2001 Jul; 56 (7): 653-9
3. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993 Jul-Aug; 38 Suppl.: 115-32
4. Solomon A, Pe'er J, Levi-Schaffer F. Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies. Curr Opin Allergy Clin Immunol 2001 Oct; 1 (5): 477-82
5. Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs 2002; 62 (11): 1611-34
6. Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2002 Jul; 2 (4): 325-31
7. Abelson MB, Kaplan A. Ocular allergies often part of a broader clinical spectrum. Ophthalmol Times 2002 May 1; 27 (9): 48-9
8. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994 Aug; 94 (2 Pt 1): 182-8
9. Blaiss MS. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999 Nov; 83 (5): 449-54
10. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001 Jul; 108 (1 Suppl.): S45-53
11. Van Wijk R Gerth. Treatment of allergic rhinoconjunctivitis: a review of the role of topical levocabastine. Mediators Inflamm 1995; 4: S31-8
12. Howarth P. Antihistamines in rhinoconjunctivitis. Clin Allergy Immunol 2002; 17: 179-220
13. Grant SM, Goa KL, Fitton A, et al. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990 Sep; 40 (3): 412-48
14. Abelson MB, Shams N, Kapik B, et al. Ocular tolerance and safety of ketotifen fumarate 0.025% ophthalmic solution compared with placebo [abstract]. Clin Experiment Ophthalmol 2002 Apr 21; 30S: A323
15. Guttman C, Abelson MB. Ketotifen active against seasonal allergic conjunctivitis. Ophthalmol Times 2000 Jun 1; 25 (11): 30
16. Onrust SV, Lamb HM. Mometasone furoate: a review of its intranasal use in allergic rhinitis. Drugs 1998 Oct; 56 (4): 725-45
17. Kyrein HJ, Horak F, Nimberger G, et al. Efficacy of intranasally applied dimethindene maleate solution as spray in adult volunteers with symptoms of seasonal allergic rhinitis in the Vienna Challenge Cchamber. Arzneimittel Forschung 1996 Aug; 46 (8): 794-9
18. Horak F, Jager S, Toth J, et al. Efficacy and tolerability of astemizole-D and Loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. Arzneimittel Forschung 1996 Nov; 46 (11): 1077-81
19. Horak F, Berger UE, Menapace R, et al. Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis: a double-blind, placebo-controlled study. Arzneimittel Forschung 1998 Apr; 48 (4): 379-84
20. Horak F, Unkauf M, Beckers C, et al. Efficacy and tolerability of intranasally applied dimetindene maleate solution versus placebo in the treatment of seasonal allergic rhinitis. Arzneimittel Forschung 2000 Dec; 50 (12): 1099-105
21. Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10mg o.d. and fexofenadine 120mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001 May; 125 (1): 73-9
22. Stubner UP, Toth J, Marks B, et al. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. Arzneimittel Forschung 2001 Nov; 51 (11): 904-10
23. Guttman C, Marioneaux SJ, Udell IJ. An agent able to antagonize histamine, stabilize mast cells [ketotifen fumarate]. Ophthalmol Times 2001 May 15; 26 (10): 22-3
24. Brunzini M, Lambrou G, Udell I. et al. Ketotifen fumarate (Zaditor) eye drops: a new treatment option for allergic conjunctivitis. Ophthalmic Pract 2001; 19 (2): 78-80
25. Abelson MB, Chapin MJ, Kapik BM, et al. Ocular tolerability and safety of ketotifen fumarate ophthalmic solution. Adv Ther 2002 Jul-Aug; 19 (4): 161-9